RARE Stock — Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. (RARE)

Updated October 16, 2026.

RARE is a Stock. Total return is -65.6% over the past 12.7 years, 495.6 points behind SPY at 430.0%.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that identifies, acquires, develops, and commercializes novel biologic treatments for rare and ultra-rare genetic diseases, with marketed products including Crysvita for X-linked hypophosphatemia, Mepsevii for Mucopolysaccharidosis VII, and Dojolvi for fatty acid oxidation disorders, alongside a pipeline of gene therapies and other candidates in clinical trials. The company does not currently have an established distribution schedule. Ultragenyx appeals primarily to growth-oriented investors seeking exposure to specialized pharmaceutical development rather than to income investors.

RARE performance versus SPY

Price and return data through 2026-10-16.

Total return is -65.6% over the past 12.7 years, 495.6 points behind SPY at 430.0%. Over the past year its total return — price change plus distributions reinvested — is -57.2%. Its deepest 1-year drawdown was 64.8%.

RARE key facts

Asset type

Stock

Asset class

Equity

Inception date

01/31/2014

Distribution frequency

None

Last close

$14.54 (as of 2026-10-16)

Market cap

$1,433,482,213

Average volume

2924015.0

Beta

0.348

Payout ratio

0.0%

Forward P/E

67.2459

EPS

$-5.82

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RARE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 64.8%.

Who may consider RARE — and who may not

It is a weaker fit for investors who need monthly cash flow (RARE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RARE

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions